Table 1 Open in new tab Patient...

Table 1

Patient characteristics

Characteristic	All patients	Intermediate-risk patients	High-risk patients
No. of patients	512	201	311
Age (years)
Median	71	70	71
Range	49–84	49–83	53–84
T classification
T1	135	88	47
T2	206	113	93
T3	167	0	167
T4	4	0	4
Gleason score
≤6	27	23	4
7	252	178	74
≥8	233	0	233
Pretreatment PSA (ng/ml)
<10	225	126	99
10-20	159	75	84
≥20	128	0	128
Median	11.3	8.1	16.0
Range	1.9–499.0	2.4–19.6	1.9–499.0
Androgen deprivation therapy
≥2 years	74	7	67
12 months	183	36	147
6 months	126	50	76
None	129	108	21
Range (years)	0–11.4	0–5.1	0–11.4
Follow-up (months)
Median	100	99	100
Range	24–154	24–149	24–154

Characteristic	All patients	Intermediate-risk patients	High-risk patients
No. of patients	512	201	311
Age (years)
Median	71	70	71
Range	49–84	49–83	53–84
T classification
T1	135	88	47
T2	206	113	93
T3	167	0	167
T4	4	0	4
Gleason score
≤6	27	23	4
7	252	178	74
≥8	233	0	233
Pretreatment PSA (ng/ml)
<10	225	126	99
10-20	159	75	84
≥20	128	0	128
Median	11.3	8.1	16.0
Range	1.9–499.0	2.4–19.6	1.9–499.0
Androgen deprivation therapy
≥2 years	74	7	67
12 months	183	36	147
6 months	126	50	76
None	129	108	21
Range (years)	0–11.4	0–5.1	0–11.4
Follow-up (months)
Median	100	99	100
Range	24–154	24–149	24–154